TITLE

Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study

AUTHOR(S)
Giorda, Carlo B.; Picariello, Roberta; Tartaglino, Barbara; Marafetti, Lisa; Di Noi, Fabiana; Alessiato, Annalisa; Costa, Giuseppe; Gnavi, Roberto
PUB. DATE
June 2015
SOURCE
BMJ Open;Jun2015, Vol. 5 Issue 6, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
103675274

 

Related Articles

  • Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes.  // BMJ: British Medical Journal;2/20/2016, Vol. 352 Issue 8045, p270 

    The article examines observational studies and randomized trials which investigated whether dipeptidyl peptidase-4 (DPP-4) inhibitors increases the risk of heart failure in type 2 diabetes patients. Topics covered include low quality evidence indicating that there is no increase in the risk of...

  • No Increased CV Events with DPP-4 Inhibitors. Buckley, Rita // MD Conference Express;Dec2011, p11 

    The article presents a study on the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors on cardiovascular (CV) events in type 2 diabetes patients. It mentions that there are no increased CV events associated with DPP-4 inhibitors. It notes that DPP-4 inhibitors provides a possible protective...

  • Hospitalisation for HF assessed with various T2DM therapies.  // Reactions Weekly;2/6/2016, Vol. 1587 Issue 1, p9 

    An abstract of the article "Association Between Hospitalization for Heart Failure and Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes: An Observational Study" by A.Z. Fu and others is presented.

  • COMMENTARY. Bolen, Shari D. // BMJ: British Medical Journal;2/20/2016, Vol. 352 Issue 8045, pi801 

    The author discusses two studies which investigated whether incretin based drugs for treatment of type 2 diabetes increase the risk of heart failure and pancreatic cancer. One of the studies found no reported increase in pancreatic cancer risk in patients taking dipeptidyl peptidase-4 (DPP-4)...

  • Prolyl Peptidases Related to Dipeptidyl Peptidase IV: Potential of Specific Inhibitors in Drug Discovery. Van der Veken, Pieter; Haemers, Achiel; Augustyns, Koen // Current Topics in Medicinal Chemistry;Mar2007, Vol. 7 Issue 6, p621 

    Dipeptidyl peptidase IV (DPP IV) is a validated target for the treatment of type 2 diabetes, with several inhibitors currently in phase 3 clinical trials. This review will mainly focus on proline-specific dipeptidyl peptidases related to DPP IV: fibroblast activation protein (FAP), dipeptidyl...

  • Type 2 Diabetes Drug Shows Promise for Type 1. Stein, Jill // Renal & Urology News;Dec2010, Vol. 9 Issue 12, p28 

    The article reports on the approval of dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin which is for the treatment of adult patients with type 2 diabetes.

  • Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study. Chou, Hsin-Chun; Chen, Wen-Wen; Hsiao, Fei-Yuan // Drug Safety;Jul2014, Vol. 37 Issue 7, p521 

    Background: Concern about an increasing risk of acute pancreatitis associated with incretin-based drugs, including dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 analogs, has emerged recently. Objective: This nested case-control study examined the association between the...

  • Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan. Wang, Szu-Heng; Chen, Dong-Yi; Lin, Yu-Sheng; Mao, Chun-Tai; Tsai, Ming-Lung; Hsieh, Ming-Jer; Chou, Chung-Chuan; Wen, Ming-Shien; Wang, Chun-Chieh; Hsieh, I-Chang; Hung, Kuo-Chun; Chen, Tien-Hsing // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Background: The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain. Methods: We analyzed data from the National Health Insurance Research Database...

  • Incretin-Based Drugs and the Risk of Congestive Heart Failure. Yu, Oriana Hoi Yun; Filion, Kristian B.; Azoulay, Laurent; Patenaude, Valerie; Majdan, Agnieszka; Suissa, Samy // Diabetes Care;Feb2015, Vol. 38 Issue 2, p277 

    OBJECTIVE To determine whether the use of incretin-based drugs, including GLP-1 analogs and dipeptidyl peptidase-4 inhibitors, is associated with an increased risk of congestive heart failure (CHF) among patients with type 2 diabetes. RESEARCH DESIGN AND METHODS The U.K. Clinical Practice...

  • INTEGRATED PHYSIOLOGY--INSULIN SECRETION IN VIVO.  // Diabetes;Jun2008 Supplement 1, Vol. 57, pA710 

    The article offers information on different studies about diabetes with topics on adiponectin and the first two types of diabetes, dipeptidyl peptidase 4 (DPP4) inhibitor, sulfonylurea-induced hypoglycemia, insulin secretion and insulin action in Chinese non-obese euglycemic first-degree...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics